Not a good buy right now for an impatient entry: trend is still bearish (SMA200 > SMA20 > SMA5) and momentum is slightly negative.
Options positioning is bullish/greedy (very low put/call), but that alone isn’t enough to offset the weak chart and lack of near-term catalysts.
Best risk/reward improves if price reclaims the pivot (~14.41) and holds; at 13.81 it’s still below that key inflection level.
Technical Analysis
Trend/Moving Averages: Bearish alignment (SMA_200 > SMA_20 > SMA_5) suggests price is in a broader downtrend/weak regime.
Momentum (MACD): Histogram -0.111 (below zero) but negatively contracting = downside momentum is easing, not yet reversed.
RSI (6): 51.0 = neutral; no oversold bounce signal.
Key levels: Pivot 14.405 (must reclaim for bullish shift). Support S1 12.98 then S2 12.10. Resistance R1 15.83.
Pattern-based forward view: Similar-pattern stats imply ~70% chance of -1.97% next day, -0.38% next week, but +5.06% next month (near-term choppy/soft, medium-term bounce potential).
Positioning/Sentiment: Put/Call ratios are extremely low (OI PCR 0.25; Volume PCR 0.12) → options market skew is strongly bullish (more calls than puts).
Activity: Today volume 336 vs 30-day average factor 28.62 (unusually elevated activity).
Open interest: Calls OI 20,946 vs puts OI 5,137 (call-heavy).
Volatility: IV30 ~97.76 with IV percentile 80 (options priced rich vs typical) → market expects large moves; good for sellers/structured trades, but it also signals uncertainty.
Technical Summary
Sell
8
Buy
4
Positive Catalysts
Options market sentiment is notably bullish (call-heavy OI and volume).
Momentum is no longer accelerating downward (MACD histogram contracting), which can precede a stabilization.
Financial trend improving: revenue and gross margin up YoY (see financials), supporting a medium-term recovery narrative.
Net income: -5.891M, improved 18.44% YoY (loss narrowing, still negative).
EPS: -0.21, improved 16.67% YoY.
Gross margin: 63.2%, +5.90% YoY (notable margin expansion—best item in the snapshot).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating changes or price target updates were provided in the dataset, so a recent Wall Street trend can’t be confirmed here.
Practical read given available info: improving revenue/margins are the likely “pro” case, while the ongoing losses and bearish technical structure are the core “con” case.
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29 USD with a low forecast of 28 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29 USD with a low forecast of 28 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.570
Low
28
Averages
29
High
30
Current: 12.570
Low
28
Averages
29
High
30
B. Riley
Buy
maintain
$20 -> $28
AI Analysis
2025-04-25
Reason
B. Riley
Price Target
$20 -> $28
AI Analysis
2025-04-25
maintain
Buy
Reason
B. Riley raised the firm's price target on ClearPoint Neuro to $28 from $20 and keeps a Buy rating on the shares following a transfer of coverage. ClearPoint is a medical device company focused on providing image-guided navigation for minimally invasive neuro procedures, the analyst tells investors in a research note. The firm says the company's core business continues to grow over 20% annually, and that it expects significant growth in the future as biopharma partnerships progress towards regulatory approvals and commercial launches.
